<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Malignant <z:hpo ids='HP_0009733'>gliomas</z:hpo> have long been a therapeutic dilemma in neuro-<z:hpo ids='HP_0002664'>oncology</z:hpo>, with a poor overall prognosis </plain></SENT>
<SENT sid="1" pm="."><plain>Standard treatment, consisting of primary resection, followed by radiation therapy and temozolomide, has improved prognosis </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, studies have looked at the addition of bevacizumab (Avastin), a humanized murine IgG1 monoclonal antibody against vascular endothelial growth factor-A, to conventional regiments </plain></SENT>
<SENT sid="3" pm="."><plain>Bevacizumab gained US FDA approval for single agent use in recurrent <z:hpo ids='HP_0100843'>glioblastoma</z:hpo> in 2009 </plain></SENT>
<SENT sid="4" pm="."><plain>Known side effects of bevacizumab include increased risk of arterial and venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, as well as <z:mp ids='MP_0001914'>hemorrhage</z:mp> </plain></SENT>
<SENT sid="5" pm="."><plain>With emerging data for the use of bevacizumab in malignant <z:hpo ids='HP_0009733'>gliomas</z:hpo>, the extent of risks such as <z:mp ids='MP_0001914'>bleeding</z:mp> and <z:mp ids='MP_0005048'>thrombosis</z:mp> in patients with primary <z:mp ids='MP_0009277'>brain tumors</z:mp> treated with bevacizumab remains unknown </plain></SENT>
<SENT sid="6" pm="."><plain>Here, we present only the second reported case of dural venous sinus <z:mp ids='MP_0005048'>thrombosis</z:mp> during treatment with bevacizumab and the first reported case for a primary <z:hpo ids='HP_0009733'>glioma</z:hpo> treated with temozolomide, radiation, and bevacizumab </plain></SENT>
</text></document>